Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic status

被引:42
作者
Hirota, T
Ieiri, I
Takane, H
Maegawa, S
Hosokawa, M
Kobayashi, K
Chiba, K
Nanba, E
Oshimura, M
Sato, T
Higuchi, S
Otsubo, K
机构
[1] Tottori Univ, Fac Med, Dept Hosp Pharm, Yonago, Tottori 6838504, Japan
[2] Kyushu Univ, Grad Sch Pharmaceut Sci, Div Clin Pharm, Fukuoka 8128582, Japan
[3] Tottori Univ, Res Ctr Biosci & Technol, Div Funct Genom, Yonago, Tottori 6838504, Japan
[4] Tottori Univ, Grad Sch Med Sci, Inst Regenerat Med & Biofunct, Dept Biomed Sci, Yonago, Tottori 6838504, Japan
[5] Chiba Univ, Grad Sch Pharmaceut Sci, Lab Biochem Pharmacol & Toxicol, Chiba 2740816, Japan
关键词
D O I
10.1093/hmg/ddh313
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The human cytochrome P450 3A4 (CYP3A4) plays a dominant role in the metabolism of numerous clinically useful drugs. Alterations in the activity or expression of this enzyme may account for a major part of the variation in drug responsiveness and toxicity. However, it is generally accepted that most of the known single nucleotide polymorphisms in the coding and 5'-flanking regions are not the main determinants for the large inter-individual variability of CYP3A4 expression and activity. We show that the allelic variation is critically involved in determining the individual total hepatic CYP3A4 mRNA level and metabolic capability. There exists a definite correlation between the total CYP3A4 mRNA level and allelic expression ratio, the relative transcript level ratio derived from the two alleles. Individuals with a low expression ratio, exhibiting a large difference of transcript level between the two alleles, revealed extremely low levels of total hepatic CYP3A4 mRNA, and thus low metabolic capability as assessed by testosterone 6beta-hydroxylation. These results present a new insight into the individualized CYP3A4-dependent pharmacotherapy and the importance of expression imbalance to human phenotypic diversity.
引用
收藏
页码:2959 / 2969
页数:11
相关论文
共 52 条
[1]   Population distribution and effects on drug metabolism of a genetic variant in the 5′ promotor region of CYP3A4 [J].
Ball, SE ;
Scatina, JA ;
Kao, J ;
Ferron, GM ;
Fruncillo, R ;
Mayer, P ;
Weinryb, I ;
Guida, M ;
Hopkins, PJ ;
Warner, N ;
Hall, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (03) :288-294
[2]   Mechanisms of genomic imprinting [J].
Brannan, CI ;
Bartolomei, MS .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 1999, 9 (02) :164-170
[3]  
BROOKS BA, 1988, AM J HUM GENET, V43, P280
[4]   Cytochrome P450 3A and their regulation [J].
Burk, O ;
Wojnowski, L .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2004, 369 (01) :105-124
[5]   Imprinting mechanisms [J].
Constancia, M ;
Pickard, B ;
Kelsey, G ;
Reik, W .
GENOME RESEARCH, 1998, 8 (09) :881-900
[6]  
Cooper D.W., 1993, Seminars in Developmental Biology, V4, P117, DOI 10.1006/sedb.1993.1014
[7]   IMPT1, an imprinted gene similar to polyspecific transporter and multi-drug resistance genes [J].
Dao, D ;
Frank, D ;
Qian, NF ;
O'Keefe, D ;
Vosatka, RJ ;
Walsh, CP ;
Tycko, B .
HUMAN MOLECULAR GENETICS, 1998, 7 (04) :597-608
[8]   Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects [J].
Eap, CB ;
Buclin, T ;
Hustert, E ;
Bleiber, G ;
Golay, KP ;
Aubert, AC ;
Baumann, P ;
Telenti, A ;
Kerb, R .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 60 (04) :231-236
[9]   Identification and functional characterization of eight CYP3A4 protein variants [J].
Eiselt, R ;
Domanski, TL ;
Zibat, A ;
Mueller, R ;
Presecan-Siedel, E ;
Hustert, E ;
Zanger, UM ;
Brockmoller, J ;
Klenk, HP ;
Meyer, UA ;
Khan, KK ;
He, YA ;
Halpert, JR ;
Wojnowski, L .
PHARMACOGENETICS, 2001, 11 (05) :447-458
[10]   The neuronatin gene resides in a "micro-imprinted" domain on human chromosome 20q11.2 [J].
Evans, HK ;
Wylie, AA ;
Murphy, SK ;
Jirtle, RL .
GENOMICS, 2001, 77 (1-2) :99-104